Sensitivity of Mycobacterium leprae to Telacebec

The treatment of leprosy is long and complex, benefiting from the development of sterilizing, rapidly-acting drugs. Reductive evolution made Mycobacterium leprae exquisitely sensitive to Telacebec, a phase 2 drug candidate for tuberculosis(.) The unprecedented potency of Telacebec against M. leprae...

Descripción completa

Detalles Bibliográficos
Autores principales: Lahiri, Ramanuj, Adams, Linda B., Thomas, Sangeeta Susan, Pethe, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888226/
https://www.ncbi.nlm.nih.gov/pubmed/35202539
http://dx.doi.org/10.3201/eid2803.210394
_version_ 1784661092821106688
author Lahiri, Ramanuj
Adams, Linda B.
Thomas, Sangeeta Susan
Pethe, Kevin
author_facet Lahiri, Ramanuj
Adams, Linda B.
Thomas, Sangeeta Susan
Pethe, Kevin
author_sort Lahiri, Ramanuj
collection PubMed
description The treatment of leprosy is long and complex, benefiting from the development of sterilizing, rapidly-acting drugs. Reductive evolution made Mycobacterium leprae exquisitely sensitive to Telacebec, a phase 2 drug candidate for tuberculosis(.) The unprecedented potency of Telacebec against M. leprae warrants further validation in clinical trials.
format Online
Article
Text
id pubmed-8888226
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-88882262022-03-02 Sensitivity of Mycobacterium leprae to Telacebec Lahiri, Ramanuj Adams, Linda B. Thomas, Sangeeta Susan Pethe, Kevin Emerg Infect Dis Research Letter The treatment of leprosy is long and complex, benefiting from the development of sterilizing, rapidly-acting drugs. Reductive evolution made Mycobacterium leprae exquisitely sensitive to Telacebec, a phase 2 drug candidate for tuberculosis(.) The unprecedented potency of Telacebec against M. leprae warrants further validation in clinical trials. Centers for Disease Control and Prevention 2022-03 /pmc/articles/PMC8888226/ /pubmed/35202539 http://dx.doi.org/10.3201/eid2803.210394 Text en https://creativecommons.org/licenses/by/4.0/Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research Letter
Lahiri, Ramanuj
Adams, Linda B.
Thomas, Sangeeta Susan
Pethe, Kevin
Sensitivity of Mycobacterium leprae to Telacebec
title Sensitivity of Mycobacterium leprae to Telacebec
title_full Sensitivity of Mycobacterium leprae to Telacebec
title_fullStr Sensitivity of Mycobacterium leprae to Telacebec
title_full_unstemmed Sensitivity of Mycobacterium leprae to Telacebec
title_short Sensitivity of Mycobacterium leprae to Telacebec
title_sort sensitivity of mycobacterium leprae to telacebec
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888226/
https://www.ncbi.nlm.nih.gov/pubmed/35202539
http://dx.doi.org/10.3201/eid2803.210394
work_keys_str_mv AT lahiriramanuj sensitivityofmycobacteriumlepraetotelacebec
AT adamslindab sensitivityofmycobacteriumlepraetotelacebec
AT thomassangeetasusan sensitivityofmycobacteriumlepraetotelacebec
AT pethekevin sensitivityofmycobacteriumlepraetotelacebec

Ejemplares similares